• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine . A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibod

tetano

Editor, Senior Moderator
Vaccine


. 2023 Sep 7;S0264-410X(23)01060-5.
doi: 10.1016/j.vaccine.2023.09.007. Online ahead of print. A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses

Jieshi Yu[SUP] 1 [/SUP], Chithra Sreenivasan[SUP] 1 [/SUP], Zhizhang Sheng[SUP] 2 [/SUP], Shao-Lun Zhai[SUP] 3 [/SUP], Jared W Wollman[SUP] 3 [/SUP], Sisi Luo[SUP] 3 [/SUP], Chen Huang[SUP] 1 [/SUP], Rongyuan Gao[SUP] 3 [/SUP], Zhao Wang[SUP] 3 [/SUP], Radhey S Kaushik[SUP] 3 [/SUP], Jane Christopher-Hennings[SUP] 4 [/SUP], Eric Nelson[SUP] 4 [/SUP], Ben M Hause[SUP] 4 [/SUP], Feng Li[SUP] 5 [/SUP], Dan Wang[SUP] 6 [/SUP]



Affiliations
Abstract

The global distribution and ongoing evolution of type A swine influenza virus (IAV-S) continue to pose significant challenges against developing broadly protective vaccines to control swine influenza. This study focuses on the hemagglutinin (HA) consensus-based approach towards developing a more broadly protective swine influenza vaccine against various H3 strains circulating in domestic pig populations. By computationally analyzing >1000 swine H3 full-length HA sequences, we generated a consensus H3 and expressed it in the context of influenza A WSN/33 reverse genetics system. The derived recombinant chimeric swine influenza virus with the consensus H3 was inactivated and further evaluated as a potential universal vaccine in pigs. The consensus H3 vaccine elicited broadly active hemagglutination inhibition (HI) antibodies against divergent swine H3N2 influenza viruses including human H3N2 variant of concern, and strains belong to genetic clusters IV, IV-A, IV-B, IV-C, IV-D and IV-F. Importantly, vaccinated pigs were completely protected against challenge with a clinical swine H3N2 isolate in that neither viral shedding nor replication in lungs of vaccinated pigs were observed. These findings warrant further study of the consensus H3 vaccine platform for broad protection against diverse swine influenza viruses.

Keywords: Broadly protective vaccine; Consensus hemagglutinin; Hemagglutination inhibition; Swine influenza.

 
Back
Top Bottom